Monday 29 September 2008

Endotis Pharma — Company Profile

Endotis Pharma
Parc Eurasanté
70, rue du Docteur Yersin
59120 Loos
France

Website: http://www.endotis.com/

ENDOTIS PHARMA is a specialty pharma company dedicated to the discovery and development of small-glyco drugs (SGDs) for applications in thrombosis and oncology. These SGDs are analogues of glycosaminoglycans, the core field of expertise of Endotis' scientists. Endotis Pharma has built a well-balanced portfolio of pre-clinical and clinical stage compounds.


Corporate Profile

Incorporated in 2003, Endotis Pharma is a specialty pharma company dedicated to the discovery and development of small-glyco drugs (SGDs) for applications in thrombosis and oncology.
These SGDs are analogues of glycosaminoglycans, the core field of expertise of Endotis' scientists. Proof of concept has already been obtained with oligosaccharides in thrombosis (veinous and arterial cardiovascular diseases) and oncology, another promising therapeutic field.
Endotis Pharma has built a well-balanced portfolio of pre-clinical and clinical stage compounds (either in-licensed or generated by the company's own R&D programmes) and currently has 28 employees (including 14 PhDs/MDs) based in Paris and Lille (France).
To date, Endotis Pharma has raised a total of 34 million euros with Sofinnova Partners (France), The Wellcome Trust (UK), Endeavour Vision (Switzerland) and NIF SMBC (Japan).

Business Strategy

Endotis business strategy consists in:
— Developing a de-risked portfolio of antithrombotic compounds from pre-clinical to clinical stages
— Leveraging its unique small-glyco drug engine in oncology

Partnering strategy:
Endotis will seek to partner antithrombotic drugs when proof of concept in man is reached, and to partner its oncology platform after proof of concept in animals is reached.
Endotis will also study other partnering opportunities.

In order to guide Endotis development, the company has built a strong management team under the leadership of Charles Woler, and assembled a Scientific Advisory Board and a Clinical Advisory Board with worldwide renowned in Glycoscience and Thrombosis.


Source: Endotis Pharma